Metal-Coordinated Phosphonate Complexes for Bisphosphonate Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current bisphosphonate compounds used to treat osteolytic metastases in breast cancer have poor bioavailability and low intestinal absorption, necessitating high doses for therapeutic effects, and their direct anti-tumor mechanisms are unclear.
Innovation Solution
Development of phosphonate-based coordination complexes comprising ligand molecules like zoledronate or risedronate bound to bioactive metals such as Mg2+, Ca2+, or Zn2+, formulated into nanocrystalline compounds with drug compositions within channels, enhancing bioavailability and therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional bisphosphonate compounds are used to treat osteolytic metastases, then therapeutic effect is achieved, but bioavailability and intestinal absorption are poor
Solution Approach 1:
The patent creates composite coordination complexes by combining bisphosphonate ligands (zoledronate or risedronate) with bioactive metal ions (Ca2+, Mg2+, Zn2+). This composite structure enhances bioavailability while maintaining therapeutic efficacy, as demonstrated by improved intestinal absorption and cellular internalization compared to conventional bisphosphonates alone.
Solution Approach 2:
The patent modifies the chemical parameters of bisphosphonate compounds by introducing metal coordination bonds and forming nanocrystalline structures with specific size distributions (average diameter of 1-1000 nm). These parameter changes in molecular structure and physical form significantly improve bioavailability and therapeutic response.
2Reliability
If high doses of bisphosphonate compounds are administered to overcome poor bioavailability, then therapeutic effect is achieved, but side effects and toxicity increase
Solution Approach 1:
By changing the molecular and physical parameters through metal coordination and nanocrystalline formation, the patent achieves improved bioavailability at lower doses, thereby reducing side effects and toxicity while maintaining therapeutic effectiveness.
Solution Approach 2:
The metal-coordinated bisphosphonate complexes exhibit enhanced pharmacological properties with reduced toxicity compared to conventional bisphosphonates, as the metal coordination modifies the compound's interaction with biological systems, improving selectivity and reducing off-target effects.
3Reliability
If conventional bisphosphonate compounds are used, then osteolytic metastasis treatment is provided, but direct anti-tumor mechanisms are unclear
Solution Approach 1:
The metal coordination complexes act as intermediary structures that facilitate the interaction between bisphosphonates and tumor cells. The complexes enhance cellular internalization and promote direct anti-tumor effects through mechanisms including tumor cell apoptosis and inhibition of angiogenesis, while also maintaining bone-targeting properties.
Solution Approach 2:
The coordination complexes provide a dual-function system that simultaneously targets bone (through bisphosphonate affinity for calcium) and exerts direct anti-tumor effects (through metal-mediated cellular interactions), thereby clarifying the anti-tumor mechanism while treating osteolytic metastasis.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The complexes demonstrate improved bioavailability and therapeutic efficacy against osteolytic metastases, offering potent anticancer effects through direct tumor cell apoptosis and angiogenesis inhibition.
Implementation Method 1
compounds comprised of phosphonate-based coordination complexes incorporating Ca2+, Mg2+, and Zn2+
Implementation Method 2
the one or more ligand molecules is zoledronate, risedronate, or another phosphonate-based compound, and wherein the bioactive metal is one of Mg2+, Ca2+, or Zn2+
Implementation Method 3
the compound is provided in a crystal with a plurality of channels, and wherein the drug composition is disposed within the plurality of channels
Implementation Method 4
These complexes have the potential to be potent anticancer agents, especially with regard to osteolytic metastases, while overcoming the shortcomings of phosphonate-based compounds (e.g., zoledronic acid or risedronic acid) alone
Implementation Method 5
direct mechanisms, such as tumor cell apoptosis, and indirect mechanisms, such as angiogenesis
Data Source
AI summary
A coordination complex comprising a phosphonate-containing ligand molecule and a bioactive metal is provided. In one aspect, the present disclosure provides a compound comprising one or more phosphonate-containing ligand molecules and a bioactive metal, wherein each ligand is coordinated to the bioactive metal through at least one phosphonate, wherein the bioactive metal is Mg2+, Ca2+, or Zn2+.